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ABSTRACT
Epidemiological data have implicated reproductive hormones as prob-
able risk factors for ovarian cancer (OCa) development. Although pitui-
tary and sex hormones have been reported to regulate OCa cell growth, no
information is available regarding whether and how they influence nor-
mal ovarian surface epithelial (OSE) cell proliferation. To fill this data
gap, this study has compared cell growth responses to gonadotropins and
sex steroids in primary cultures of human OSE (HOSE) cells with those
observed in immortalized, nontumorigenic HOSE cells and in OCa cell
lines. Both malignant and normal cell lines/cultures responded equally
well to the stimulatory actions of luteinizing hormone and follicle-stimu-
lating hormone and to 17-estradiol and estrone, although the latter
estrogen has a much lower affinity for estrogen receptor than does the
former estrogen. In normal HOSE cell cultures/lines, 5-dihydrotestos-
terone was found to be more effective than testosterone in stimulating cell
growth, but in OCa cell lines, 5-dihydrotestosterone and testosterone are
equally potent. One OCa cell line, OVCA 433, was found to be nonre-
sponsive to androgen stimulation. In general, primary cultures of normal
HOSE cells exhibited the greatest hormone-stimulated growth responses
(>10-fold enhancement), followed by immortalized HOSE cell lines (4–
5-fold enhancement) and by OCa cell lines (2–4-fold enhancement). In-
terestingly, progesterone (P4), at low concentrations (1011 to 1010 M),
was stimulatory to HOSE and OCa cell growth, but at high doses (108 to
106 M), P4 exerted marked inhibitory effects. In all cases, cotreatment of
a cell culture/line with a hormone and its specific antagonist blocked the
effect of the hormone, confirming specificity of the hormonal action.
Taken together, these data support the hypothesis that reproductive states
associated with rising levels of gonadotropins, estrogen, and/or androgen
promote cell proliferation in the normal OSE, which favors neoplastic
transformation. Conversely, those states attended by high levels of circu-
lating P4, such as that seen during pregnancy, induce OSE cell loss and
offer protection against ovarian carcinogenesis.
INTRODUCTION
OCa3 varies widely in frequency among different geographic re-
gions and ethnic groups, with high incidences observed in the Scan-
dinavia, Western Europe, and North American and low incidences
found in Asian countries (1). The majority of cases are sporadic,
whereas about 5–10% of OCa cases are familial. Although all cell
types of the human ovary may undergo neoplastic transformation, the
vast majority (80–90%) of benign and malignant tumors are derived
from the OSE and its cystic derivatives (2). The origin of OSE could
be traced to the mesothelium of the embryonic gonads, or the Mul-
lerian epithelium; therefore, ovarian tumors often resemble those of
the fallopian tube, endometrium, and endocervix (2, 3).
Although the etiology of OCa remains poorly understood, evidence
is mounting to indicate the involvement of gonadotropins and/or sex
hormones in its etiology. Because OCa incidence increases dramati-
cally in women above the age of 45 years and peaks at 10–20 years
after menopause, it has been suggested that elevated levels of go-
nadotropins during this reproductive period are risk factors for the
cancer (4–7). The gonadotropin theory is further supported by several
case studies reporting development of OCa shortly after ovulation
induction with fertility drugs such as clomiphene citrate or gonado-
tropins (7, 8). It has also been proposed that entrapment of OSE cells
in inclusion cysts increases the odds of OSE neoplastic transforma-
tion, possibly due to exposure of these cells to a stromal hormonal
milieu rich in androgens (2, 9, 10). In support of the androgen theory
is the observation that women with polycystic ovary syndrome have a
higher risk of developing OCa, which is likely attributable to the
higher levels of androgen present in their circulation. With regard to
estrogens, earlier data are in inconclusive in demonstrating a positive
relationship between estrogen usage and OCa risk (11–15). However,
recent large-scale epidemiological studies (16–18) consistently dem-
onstrate that postmenopausal usage of estrogen elevates OCa inci-
dence in a manner dependent on usage duration. Finally, epidemio-
logical data have established pregnancy, particularly one that occurs
in late life, as a protective factor against OCa development (19). These
findings, in conjunction with laboratory studies (20, 21) demonstrat-
ing induction of apoptosis in OCa cell lines by P4, raise the possibility
that progestins are protective against ovarian carcinogenesis. Taken
together, these theories strongly argue for major roles played by
reproductive hormones, such as those associated with the female
cycle, pregnancy, perimenopause, and postmenopause, in ovarian
carcinogenesis.
According to modern concept of hormonal carcinogenesis (22),
endogenous and exogenous hormones enhance cell proliferation and
thus enhance the opportunity for the accumulation of random genetic
errors and the emergence of malignancy. Previous studies on hor-
mones and OCa were focused primarily on the effects of pituitary
and/or sex hormones on OCa cell growth (23–38). To the best of our
knowledge, no information is available regarding whether and how
key reproductive hormones regulate the growth of normal OSE cells.
Answers to these questions are critical to our understanding of hor-
mone-induced tumor initiation in the OSE. To fill this data gap, in this
study, we have simultaneously compared the impacts exerted by
gonadotropins and key sex steroids on primary cultures of HOSE cells
with those observed in immortalized, nontumorigenic HOSE cells (39,
40) and in OCa cell lines (39). Because women are exposed to a great
variety of endogenous hormones at wide concentration ranges during
their lifetime, we have chosen to study the growth responses of
HOSE/OCa cells to the predominant premenopausal estrogen, E2, the
major postmenopausal estrogen, E1, the circulating androgen, T, the
cellular androgen, DHT, the pregnancy hormone P4, and the gonado-
tropins FSH and LH at a wide dose range (1011 to 106 M). Direct
Received 4/12/01; accepted 7/17/01.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by Army Ovarian Cancer Research Program Grant DAMD17-99-1-9563
(to S. C. M. and S-M. H.) and NIH Grant CA78523 (to S. C. M.). Part of this work will
be used to fulfill Gregory Ulinski’s Master Degree Dissertation requirement at the
Worcester Polytechnic Institute (Worcester, MA).
2 To whom requests for reprints should addressed, at Department of Surgery, Univer-
sity of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655.
Phone: (508) 856-1909; Fax: (508) 856-8699; E-mail: shuk-mei.ho@umassmed.edu.
3 The abbreviations used are: OCa, ovarian cancer; OSE, ovarian surface epithelial;
HOSE, human OSE; LH, luteinizing hormone; LH-R, LH receptor; FSH, follicle-stimu-
lating hormone; FSH-R, FSH receptor; RT-PCR, reverse transcription-PCR; E1, estrone;
E2, 17-estradiol; T, testosterone; DHT, 5-dihydrotestosterone; P4, progesterone; FBS,
fetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
PKA, protein kinase A; AR, androgen receptor; ERT, estrogen replacement therapy.
6768
cell counting or a surrogate cell proliferation assay was used to
quantify cell growth responses, and specific hormone antagonists
were used to demonstrate specificity. Semiquantitative RT-PCR was
used to demonstrate expression of FSH-R and LH-R in normal HOSE
cells for the first time. Our data now show that gonadotropins,
estrogens, and androgens are positive regulators of HOSE and OCa
cell growth, whereas P4 is a negative regulator for both cell types.
MATERIALS AND METHODS
Primary Cell Cultures and Cell Lines. Four normal primary HOSE cell
cultures (HOSE 693, HOSE 770, HOSE 783, and HOSE 785), four immor-
talized normal HOSE cell lines (HOSE 642, HOSE 301, HOSE 306, and
HOSE 12-12), and four OCa cell lines (OVCA 420, OVCA 429, OVCA 432,
and OVCA 433) were used in this study. The normal HOSE cell primary
cultures, HOSE 693, HOSE 770, HOSE 783, and HOSE 785, were obtained
from surface scrapings of normal ovaries removed from a 32-year-old patient
with adenocarcinoma of the cervix, a 42-year-old patient with moderately
differentiated squamous cell carcinoma of the cervix, a 42-year-old patient
with leiomyoma, and a 72-year-old patient with inflamed bladder mucosa,
respectively. The immortalized normal HOSE cell lines, HOSE 642, HOSE
301, HOSE 306, and HOSE 12-12, were established by human papillomavirus
E6/E7 immortalization (39) of normal HOSE cells obtained from a 46-year-old
patient with normal tissue, a 47-year-old patient with endometrioid adenocar-
cinoma of the ovary, a 53-year-old patient with breast cancer, and 39-year-old
patient with ovarian stromal hyperplasia, respectively. OCa cell lines (OVCA
420, OVCA 429, OVC A432, and OVCA 433) were established cell lines
derived from freshly isolated ascites or tumor explants obtained from patients
with late-stage serous ovarian adenocarcinomas according to Tsao et al. (39).
The epithelial nature of the HOSE cell primary cultures and the HOSE cell
lines was verified by immunostaining for K7, K8, K18, and K19 cytokeratins
and vimentin as described previously (39). The HOSE cell primary cultures
and immortalized cell lines exhibited uniform epithelial-like morphology;
immunopositivity for cytokeratins K7, K8, K18, and K19; and immunonega-
tivity for vimentin. The immortalized HOSE cell lines were shown to be
nontumorigenic in nude mice and express no CA-125 (39). In addition, they
responded to transforming growth factor -induced growth inhibition (39). In
contrast, the OCa cell lines (OVCA 420, OVCA 429, OVCA 432, and OVCA
433) expressed high levels of CA-125 and failed to respond to transforming
growth factor -induced growth arrest (39).
These cell lines were cultured and maintained at 37°C in a 5% CO2
humidified atmosphere in medium 199 (Sigma Chemical Co., St. Louis, MO)
and MCDB 105 (1:1; Sigma Chemical Co.) supplemented with 10% FCS
(Sigma Chemical Co.), 100 units/ml penicillin (Sigma Chemical Co.), and 100
g/ml streptomycin (Sigma Chemical Co.) under 5% CO2. Normal and ma-
lignant cells grown in this medium after two or more passages exhibited
uniform epithelium-like morphology.
Cell Proliferation Assay. Cell lines or primary cultures cultured in me-
dium 199:MCDB 105 (1:1) were harvested when they reached 80% conflu-
ence, washed twice in PBS, and then plated into the wells of 96-well micro-
culture plates at a density of 1000 cells/well in medium containing 10%
activated charcoal (Sigma Chemical Co.)/dextran-70 (Pharmacia)-treated FBS.
Forty-eight h after cell plating, the medium was replaced with the same
medium containing either human FSH (Calbiochem, San Diego, CA; purity,
99%; contamination with growth factors, 1%), human LH (Calbiochem;
purity, 99%; contamination with growth factors, 1%), E2 (Sigma Chemical
Co.), E1 (Sigma Chemical Co.), DHT (Sigma Chemical Co.), T (Sigma
Chemical Co.), or P4 (Sigma Chemical Co.). To study the synergistic action of
FSH and E2 on cell growth, cells were cultured with a combination of E2 and
FSH. Steroids were solubilized in absolute ethanol. The exposure concentra-
tions ranged from 1011 to 106 M for each hormone. The final concentration
of ethanol in the medium was 0.1%. The control cells were exposed to ethanol
vehicle without the testing hormone. The cells were treated with hormones for
5 days, with a fresh addition of hormone to ensure stable bioavailability.
Because DHT was metabolized rapidly, cells were subjected to DHT treatment
every 12 h. Cell proliferation was measured by a MTT cell proliferation kit
(Roche Diagnostics, Indianapolis, IN). After the incubation period, 10 l of the
MTT labeling reagent (final concentration, 0.5 mg/ml) were added to each
well, and plates were incubated for 4 h in a humidified atmosphere. Finally,
100 l of solubilization solution were added to each well, and plates were
incubated overnight at 37°C. Cell growth was measured based on the cellular
conversion of a tetrazolium compound to a colored formazan product over a
period of 18 h. At the end of the incubation period, the amount of formazan
formed was measured as absorbance at 570 nm in a spectrophotometer to
determine the cell number in each well. Assays were performed in triplicate to
generate mean values for the control and for each treatment group. Cell
number, as measured by the rate of formazan formation, in control wells with
untreated cells was arbitrarily assigned a value of 1. Relative cell growth was
expressed as the fold increase over control untreated cultures. Data points in all
figures are group mean values  SDs from three separate experiments.
Treatment of Normal and Malignant HOSE Cells with Hormones in the
Absence and Presence of Hormone Receptor Antagonists. Primary cultures
of normal HOSE cells (HOSE 693, HOSE 770, HOSE 783, and HOSE 785),
immortalized normal HOSE cell lines (HOSE 642, HOSE 301, HOSE 306, and
HOSE 12-12), and OCa cell lines (OVCA 420, OVCA 429, OVCA 432, and
OVCA 433) were seeded at 2  105 cells/T-25 flask (Falcon; Becton Dick-
inson Labware, Bedford, MA; 25-cm2 culture area), allowed to attach during
a 24-h period, and exposed to 108 M of either FSH, LH, E2, T, or P4 in the
presence or absence of the respective receptor or signaling antagonist. This
dose was selected based on the results obtained from the cell proliferation
assay, which demonstrated that for all hormones tested, this dose was at the
midpoint of the dose-response curve. Two doses of receptor antagonist were
used to block the action of the hormone. For FSH and LH, concentrations of
105 and 104 M of the PKA-selective inhibitor H89 (N-[2-(p-bromocinnam-
li)ethyl]-5-isoquinolinessulfonamide; 2HCL; Calibiochem) were added 30 min
before treatment with 108 M of the gonadotropins. H89 has been shown to be
a specific inhibitor of PKA (Ki value, 0.048 M) and to effectively block FSH
and LH action at 104 M (41). For sex steroids, receptor-specific antagonists
were used. A low (105 M) and a high (104 M) concentration of ICI 182,780
(a generous gift from Zeneca Pharmaceuticals, Macclesfield, United King-
dom), a pure estrogen receptor antagonist (42), 4-hydroxy flutamide (Schering,
Kenilworth, NJ), an AR antagonist (43), or RU 38486 (Sigma Chemical Co.),
a specific P4 receptor antagonist (44), were used to inhibit the action of E2, T,
or P4, respectively. The dosages of an antihormone used were based on
literature reports of effective receptor antagonistic effect. The cell cultures
were treated daily with hormones and hormone antagonists for a period of 5
days. After the treatment period, cell growth was determined by direct cell
count on multiple aliquots of the cultures. Each experiment was carried out
twice. The results are the means of two independent experiments.
RNA Isolation and Semiquantitative RT-PCR. Untreated normal and
malignant HOSE cells were harvested from cell cultures when they reached
approximately 70–80% confluence. Total cellular RNA was isolated using Tri
reagent (Sigma Chemical Co.) according to protocols provided by the manu-
facturer. Multiple cautionary steps were routinely taken to ensure RNA quality
and linearity of the semiquantitation method. The quality of each cellular RNA
sample was checked carefully and controlled by the following steps: (a)
measurement of absorbance at 260 and 280 nm; (b) running of a denaturing
RNA gel capable of detecting possible RNA degradation, as judged by the
integrity and intensity of the 18S and the 28S rRNA signals; and (c) conducting
semiquantitative RT-PCR amplification of the 18S rRNA at low cycle numbers
to ensure RNA quality and linearity of transcript quantification.
To investigate the relative expression levels of FSH-R and LH-R mRNA,
semiquantitative RT-PCRs were performed. The oligonucleotide primers used
to amplify human FSH-R and LH-R cDNA were previously published se-
quences (45, 46). The forward primer sequence for FSH-R amplification was
5-GAGAGCAAGGTGACAGAGATTCC-3 (nucleotides 97–120), and the
reverse primer sequence was 5-CCTTTGGAGAGAATGAATCTT-3 (nucle-
otides 417–439). For human LH-R amplification, the sense primer was 5-
CTTGGATATTTCCCACACAAA-3 (nucleotides 676–698), and the anti-
sense primer was 5-TGGCATGGTTATAGTACTGGC-3 (nucleotides
1270–1290). For amplification of human 18 S rRNA, the sense primer was
5-TGAGGCCATGATTAAGAGGG-3, and the antisense primer was 5-
CGCTGAGCCAGTCAGTGTAG-3. The amplimers from cDNA of FSH-R,
LH-R, and 18S ribosomal mRNA were 343, 615, and 623 bp, respectively.
An equal amount of total RNA (1–3 g) from the cellular total RNA sample
was reverse-transcribed into cDNA using the GeneAmp RNA PCR kit (Perkin-
Elmer, Foster City, CA). Aliquots (1–2 l of 50 l) of cDNA were subjected
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to hot-start PCR using AmpliTaq Gold DNA polymerase (Perkin-Elmer). The
enzyme was activated by preheating the reaction mixtures at 95°C for 6 min
before thermal cycling. This protocol was chosen to minimize nonspecific
product amplification. Initially, to determine the conditions under which PCR
amplification for FSH-R, LH-R, and 18S ribosomal mRNA was in the loga-
rithmic phase, different amounts of total RNA were reverse transcribed, and
aliquots were amplified using a different number of cycles. A linear relation-
ship was observed between the amount of RNA and PCR products when 3 g
of total RNA were used in the reverse transcription reaction and when 35, 30,
and 18 PCR amplification cycles were performed for FSH-R, LH-R, and 18S
rRNA, respectively. PCR for 18S rRNA was used as a control to rule out the
possibility of RNA degradation and to control the variation in mRNA concen-
tration in the RT reaction. The PCR program was 1 min at 94°C, 1 min at 60°C
(annealing temperature), and 1 min at 72°C. mRNA-specific modifications
included an annealing temperature of 58°C for amplification of FSH-R cDNA
and an annealing temperature of 55°C for amplification of LH-R. The PCR
products were fractionated on a 2% agarose gel and visualized by ethidium
bromide staining. The fluorescence images were visualized under UV transil-
lumination, captured on 665 negative film (Polaroid Co., Cambridge, MA), and
converted into digitized signals with an image scanner, and the intensities of
each band, which were derived from the area under each peak, were quantified
by ImageQuant (Molecular Dynamics, Sunnyvale, CA). Signal intensities of
FSH-R and LH-R amplimers were normalized to those of 18S rRNA products.
Message levels were expressed as the ratio of the signal intensity of the PCR
product of the receptor message to that of the 18S rRNA to produce arbitrary
units of relative abundance. The reproducibility of the quantitative measure-
ments was evaluated by three independent cDNA synthesis and PCR runs from
each preparation of RNA. The means of the replicated measurements were
calculated and are shown in the figures.
Statistical Analyses. Statistical analysis was carried out using ANOVA,
followed by Tukey’s post hoc test. Values are presented as the mean SD and
are considered significant at P  0.05.
RESULTS
Transcripts of FSH-R and LH-R Are Expressed in Normal and
Malignant HOSE Cells. The expression of FSH-R mRNA and LH-R
mRNA in normal and malignant HOSE cells was investigated by
semiquantitative RT-PCR. RT-PCR analyses of total cellular RNA
prepared from four primary cultures of normal HOSE cells, four
immortalized normal HOSE cell lines, and four OCa cell lines re-
vealed that transcripts of FSH-R and LH-R were present in all cell
cultures/lines (Fig. 1, A and C). Relative FSH-R mRNA expression
levels in the four OCa cell lines were higher than those found in
normal HOSE cells in primary cultures or in immortalized cell lines
(Fig. 1B). Conversely, relative LH-R mRNA expression levels in
normal HOSE cell cultures/lines were higher than those observed in
OCa cell lines (Fig. 1D). Nonetheless, the differences in receptor
expression levels between normal and malignant HOSE cell lines
were not dramatic.
Because we have used four different cell lines in each group, a
representative cell line from each group (primary cultures, immortal-
ized normal HOSE cells, and OCa cells) is shown in Figs. 2–5. In
addition to the representative cell lines, any cell line that showed
divergence in response to hormones compared with the other cell lines
in the group is shown under the respective group.
FSH and LH Are Equally Potent in Stimulating Normal and
Malignant HOSE Cell Growth. The effects of a 5-day treatment
with FSH or LH at a dose range between 1011 and 106 M on the
proliferation of normal and malignant HOSE cells were investigated.
FSH and LH enhanced cell proliferation in primary cultures of normal
HOSE cells (HOSE 693, HOSE 770, HOSE 783, and HOSE 785), in
immortalized normal HOSE cell lines (HOSE 642, HOSE 301, HOSE
306, and HOSE 12-12), and in OCa cell lines (OVCA 420, OVCA
429, OVCA 432, and OVCA 433) compared with cell growth in the
absence of hormonal stimulation. A representative cell line from
primary cultures (HOSE 770), immortalized normal HOSE cells
(HOSE 642), and OCa cell lines (OVCA 420) is shown in Fig. 2A.
The hormone-induced cell growth exhibited a clear dose dependency,
and both gonadotropins were found to be equally potent in stimulating
cell growth in all cell cultures/lines. However, in the immortalized
HOSE 12-12 cell lines, FSH might be more effective than LH in
stimulating cell growth (Fig. 2A). Although gonadotropin signifi-
cantly enhanced cell growth of all normal and cancerous HOSE cell
cultures/lines, normal HOSE cells in primary cultures exhibited the
best responses (8–14-fold increases), followed by those displayed in
Fig. 1. Detection of mRNA for human FSH-R and
human LH-R transcripts in total RNA samples from nor-
mal primary, normal immortalized, and malignant HOSE
cell lines. Four normal primary (HOSE 693, HOSE 770,
HOSE 783, and HOSE 785), normal immortalized (HOSE
642, HOSE 301, HOSE 306, and HOSE 12-12), and
malignant OSE cell lines (OVCA 420, OVCA 429,
OVCA 432, and OVCA 433) were used to isolate total
RNA. Semiquantitative RT-PCRs were performed as de-
scribed in “Material and Methods.” Open columns repre-
sent the relative abundance of (A) FSH-R mRNA and (C)
LH-R mRNA in individual primary HOSE cell cultures,
immortalized HOSE cell lines, and OCa cell lines. Three
independent RT-PCRs were performed with total RNA of
primary HOSE cell cultures, immortalized HOSE cell
lines, and OCa cell lines. Relative mRNA levels were
expressed as arbitrary units derived from signal intensities
of ethidium bromide-stained PCR products of the target
cDNA normalized to those of 18S rRNA cDNA. The open
columns and error bars represent the mean relative
mRNA abundance  SD (n  3). The black columns
represent group means of FSH-R (B) and LH-R (D)
mRNA levels of all four primary HOSE cultures, four
immortalized HOSE cell lines, and four OCa cell lines in
each group. The data are shown as the means  SD. ,
statistically significant difference between mean transcript
levels in OCa cell lines and those observed in primary
HOSE cell cultures at P  0.05.
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immortalized normal HOSE cell lines (5–7-fold increases) and in OCa
cell lines (3–4-fold increases; results not shown).
It is now well accepted that gonadotropins interact with their
cognate receptors and activate a stimulatory G-protein that leads to an
induction of cyclic AMP, followed by activation of PKA and subse-
quent biological responses. To ascertain whether the observed go-
nadotropin-stimulated cell growth is mediated via a receptor-triggered
PKA signaling pathway, cell cultures/lines were treated with FSH or
LH (at 108 M) for 5 days in the presence or absence of a PKA-
selective antagonist, H89 (at either 105 or 104 M). Exposure of cells
to H89 abolished the gonadotropin-induced cell growth enhancement
in normal and malignant HOSE cell cultures/lines in a manner de-
pendent on the dose of the PKA antagonist (Fig. 2B). Furthermore,
H89 by itself had no effect on cell growth.
E2 and E1 Are Equally Effective in Stimulating Normal and
Malignant HOSE Cell Growth. When increasing concentrations
(1011 to 106 M) of E1 or E2 were added to primary cultures of
normal HOSE cells (HOSE 639, HOSE 783, HOSE 785, and HOSE
770; HOSE 770, representative cell line shown in Fig. 3A), immor-
talized normal HOSE cell lines (HOSE 642, HOSE 301, HOSE 306,
and HOSE 12-12; HOSE 642, representative cell line shown in Fig.
3A), and OCa cell lines (OVCA 420, OVCA 429, OVCA 432, and
OVCA 433; OVCA 420, representative cell line shown in Fig. 3A), a
dose-dependent increase in cell growth was observed in cell cultures
challenged with an estrogen. An approximately 10–14-fold increase
in cell growth was noted in primary cultures of normal HOSE cells
exposed to the highest concentration (106 M) of E1 or E2 (results not
shown). In contrast, both estrogens at this dose only induced a 6-fold
increase in cell growth in immortalized normal HOSE cell lines and a
3–4-fold increase in cell growth in OCa cell lines (results not shown).
E1 and E2 were equally effective in enhancing cell proliferation in all
cell lines studied, with the exception of HOSE 12-12 cells, which
responded better to E1 than to E2 (Fig. 3A). Simultaneous treatment of
cell cultures/lines with E2 and FSH induced no additive effect on
enhancement of cell growth (results not shown).
When normal and malignant HOSE cells were exposed to a 5-day
treatment with 108 M E2 in the presence or absence of ICI 182,780
(105 or 104 M), a marked attenuation in E2-induced growth en-
hancement was observed in cultures exposed to the antiestrogen (Fig.
3B). ICI 182,780 is recognized as a pure antiestrogen, and it has been
shown to inhibit the action of both estrogen receptor- and estrogen
receptor- (44).
Differential Responsiveness of Normal and Malignant HOSE
Cells to DHT- and T-induced Cell Growth Enhancement. Testos-
terone and DHT significantly stimulated cell growth in primary cul-
tures of normal HOSE cells (HOSE 639, HOSE 783, HOSE 785, and
HOSE 770), immortalized normal HOSE cell lines (HOSE 642,
HOSE 301, HOSE 306, and HOSE 12-12), and malignant OCa cell
lines (OVCA 420, OVCA 429, and OVCA 432, but not OVCA 433).
The responses of HOSE 770, the representative cell line for primary
Fig. 2. Effect of FSH and LH on cell proliferation in normal primary HOSE, immortalized HOSE, and OCa cells. Representative cell lines from each group and any cell line that
showed divergence from the other cell lines in a group are shown under the representative cell line. Primarily HOSE (HOSE 693, HOSE 770, HOSE 783, and HOSE 785), immortalized
HOSE (HOSE 642, HOSE 301, HOSE 306, and HOSE 12-12), and malignant OCa (OVCA 420, OVCA 429, OVCA 432, and OVCA 433) cells were cultured at a density of (A) 1000
cells/well in a 96-well plate in medium 199:MCDB 105 supplemented with 10% FBS (heat-inactivated, charcoal-stripped FBS) and 100 units/ml penicillin-streptomycin for MTT assay.
After preincubation for 48 h, the cells were treated with different concentrations (1011 to 106 M) of FSH (F) or LH (E) for 5 days. The cell growth was assessed by MTT assay
as described in “Materials and Methods.” The absorbance of wells not exposed to hormones was arbitrarily set as 1, and FSH- and LH-treated cell growth was expressed as the fold
increase compared with the control. The representative cell line from primary HOSE (HOSE 770), immortalized HOSE (HOSE 642), and malignant OCa (OVCA 420) is shown. The
immortalized HOSE line (HOSE 12-12) that showed divergence from the other lines in the group is shown under the representative cell line. B, to confirm the specificity of FSH and
LH, 2  105 cells/T-25 flask were cultured alone (u) or cotreated with 108 M of either FSH or LH (p) and two doses of the PKA inhibitor H89 (105 M, f; z, 104 M) for 5 days.
The control cells were treated with vehicle. After 5 days, the number of cells was counted. Treatment of cells with FSH and LH induced proliferation of cells in a dose-dependent
manner. Cotreatment with PKA blocker H89 abolished the response of normal HOSE cells to gonadotropins. The data are shown as the mean of two experiments with triplicate samples
and represent the mean  SD. , P  0.05.
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HOSE cells, HOSE 642, the representative cell line for immortalized
HOSE cells, and OVCA 420, the representative cell line for malignant
cells, are shown in Fig. 4A. Primary cell cultures of normal HOSE
cells (HOSE 770, Fig. 4A) and immortalized normal HOSE cell lines
(HOSE 642, Fig. 4A) were more responsive to DHT than T, whereas
the OCa cell lines (Fig. 4A) responded equally well to both androgens.
Although all of the immortalized normal HOSE cell lines were extra
receptive to DHT, HOSE 306 showed a greater sensitivity to DHT
(Fig. 4A). The OCa cell line OVCA 433 failed to respond to both T
and DHT stimulation (Fig. 4A). The androgen-induced cell growth
enhancement was found to be dose dependent (Fig. 4A) and reversible
by cotreatment of cells with the antiandrogen 4-hydroxy flutamide
(Fig. 4B) in all of the cell lines tested.
P4 Exerts Both Stimulatory and Inhibitory Effects on Normal
and Malignant HOSE Cell Growth. The effects of P4 on cell
proliferation in normal and malignant HOSE cell cultures/lines were
investigated over a wide concentration range of 1011 to 106 M.
Results revealed that the steroid could stimulate and inhibit cell
growth of normal and malignant HOSE cells depending on the dosage
of exposure. All of the primary cell cultures of normal HOSE cells
(HOSE 783, HOSE 785, and HOSE 770; HOSE 770 is shown as the
representative cell line in Fig. 5A) except HOSE 693 (Fig. 5A) showed
stimulation of cell growth when exposed to low concentrations of P4.
Exposure to low concentrations (1011 to 109 M) of P4 induced cell
growth enhancement in two immortalized normal HOSE cell lines
[HOSE 306 (Fig. 5A) and HOSE 301 (data not shown)], whereas the
other two cell lines, HOSE 642 (shown in Fig. 5A) and HOSE 12-12
(data not shown), did not show any increase in cell number. OCa cell
lines OVCA 432, OVCA 433, and OVCA 420 (OVCA 420 is the
representative cell line shown in Fig. 5A) showed enhancement of cell
proliferation in response to low concentrations (1011 to 109 M) of
P4, whereas the OCa cell line OVCA 429 failed to show proliferation
of cells in response to low doses of P4 (Fig. 5A). However, when
normal and malignant HOSE cell cultures/lines were challenged with
higher doses of P4 (108 to 106 M), the steroid consistently led to
growth inhibition (Fig. 5A, see the representative lines shown for each
group). Interestingly, the lowest dose of P4 (1011 M) induced the
most cell growth enhancement in responsive cell cultures/lines,
whereas the growth-inhibitory effect of P4 was clearly dose depend-
ent, with the higher doses being more effective. Cotreatment of
normal and malignant HOSE cells with the progestin antagonist, RU
38486, at 105 or 104 M reversed the growth-inhibitory effects of
108 M P4 in all cell lines/cultures (Fig. 5B). The latter finding
suggests that the antiproliferative effect of P4 on all of the cell
cultures/lines is mediated via the P4 receptor.
DISCUSSION
A major goal of this research was to fill a data gap regarding the
lack of information on hormonal regulation of normal HOSE cell
growth. Additionally, an equally important aim was to generate in-
vestigational data to explain epidemiological findings that have im-
plicated hormones as risk factors for OCa. In this investigation, we
capitalized on our unique access to normal HOSE cells as primary
Fig. 3. Effect of E2 and E1 on cell proliferation in normal primary HOSE, immortalized HOSE, and malignant cells. Primarily HOSE (HOSE 693, HOSE 770, HOSE 783, and HOSE
785), immortalized HOSE (HOSE 642, HOSE 301, HOSE 306, and HOSE 12-12), and OCa (OVCA 420, OVCA 429, OVCA 432, and OVCA 433) cell lines were cultured as described
in the legend of Fig. 2. After preincubation for 48 h in heat-inactivated charcoal-stripped FBS, the cells were treated with different concentrations (1011 to 106 M) of E2 (Œ) or E1
(‚) for 5 days. The cell growth was assessed by MTT assay as described in “Materials and Methods.” The absorbance of wells not exposed to hormones was arbitrarily set as 1, and
E2- and E1-treated cell growth was expressed as the fold increase compared with the control. The representative cell line from primary HOSE (HOSE 770), immortalized HOSE (HOSE
642), and malignant (OVCA 420) cells is shown. The immortalized HOSE cell line (HOSE 12-12) that showed divergence from the other cell lines in the group is shown under the
representative cell line. B, to confirm the specificity of E2, 2  105 cells/T-25 flask were cultured alone (u) or cotreated with 108 M of E2 (p) and two doses of ICI 182,780 (105
M, f; 104 M, z) for 5 days. The control cells were treated with vehicle. After 5 days, the number of cells was counted. Treatment of cells with E2 and E1 induced proliferation of
cells in a dose-dependent manner. Cotreatment with ICI 182,780 abolished the response of normal HOSE cells to E2. The data are shown as the mean of two experiments with triplicate
samples and represent the mean  SD. , P  0.05.
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cultures or immortalized lines to conduct a comparative study to
determine cell growth responses induced by gonadotropins and key
sex steroids in these cells and in their malignant counterparts. We
reported here, for the first time, coexpression of LH-R and FSH-R in
normal HOSE cell cultures and immortalized lines. Both gonado-
tropins (LH and FSH) and the two estrogens (E1 and E2) were equally
potent in enhancing cell growth in normal and malignant HOSE cells.
The cellular androgen, DHT, was more effective than the circulating
androgen, T, in stimulating the growth of normal HOSE cells in
primary cultures, but the two androgens were equally potent in en-
hancing proliferation of OCa cells. Overall, primary cultures of nor-
mal HOSE cells exhibited the greatest responses to gonadotropin-,
estrogen-, or androgen-stimulated cell growth when compared with
those observed in immortalized HOSE cell lines or in OCa cell lines.
Importantly, P4 at low doses was a promoter, but at higher doses, it
was an unvaried growth inhibitor of normal and malignant HOSE cell
growth.
Indirect evidence suggests that gonadotropins may have a role in
the genesis and promotion of epithelial OCa (7, 9, 16). The incidence
of OCa peaks 10–20 years after menopause, when gonadotropin
levels are elevated. Case studies have reported development of epi-
thelial OCa in women undergoing fertility treatment, and an increased
OCa risk has been reported in association with the use of fertility
drugs in population studies (7, 8). A handful of laboratory studies
have demonstrated that gonadotropins influence cell growth in some
but not all OCa cell lines (23, 25, 26). In early studies (47–50),
gonadotropin-binding sites were found in OCa cells. In recent studies
(26, 51), transcripts of FSH-R and LH-R were detected in the great
majority of ovarian tumors. In this study, we reported coexpression of
FSH-R and LH-R transcripts in normal HOSE cells at levels compa-
rable with those found in OCa cell lines. Both FSH and LH, at doses
as low as 1011 to 1010 M, were stimulatory for normal and malig-
nant HOSE cell growth. These doses translate to approximately 20–
200 mIU/ml gonadotropin, concentrations that are well within the
ranges of circulating FSH and LH reported in women. The circulating
levels of FSH and LH in cycling women fluctuate between 10–25 and
18–50 mIU/ml, respectively (52). After menopause, circulating go-
nadotropins are elevated to levels around 66 mIU/ml for FSH and 23
mIU/ml for LH (53). In our experiments, the effects of FSH and LH
on cell growth enhancement were blocked by the selective PKA
inhibitor, H89, providing evidence of specificity for the gonadotropin
action. When compared over a wide dose range, FSH and LH were
found to be equally potent in stimulating normal and malignant HOSE
cell growth. The latter finding is clearly in disagreement with a recent
study (26) that found FSH and LH to have opposite effects in the
growth regulation of two OCa cell lines, AO and 3AO, with FSH as
the stimulator and LH as the inhibitor. Interestingly, we found normal
HOSE cells in primary cultures to be more responsive to gonadotropin
stimulation, producing a 10–14-fold increase in cell growth enhance-
ment, as compared with a 3–5-fold increase in immortalized normal
HOSE cell lines and OCa cell lines. This observation suggests that
normal HOSE cells are hypersensitive to gonadotropin stimulation
and may therefore undergo excessive cell proliferation under a post-
menopausal hormonal milieu and be susceptible to malignant trans-
formation. All in all, our findings are in accord with the theory that
suggests rising levels of gonadotropins as a risk factor for OCa and are
in disagreement with the hypothesis that high levels of gonadotropins
are protective against OCa development (54).
Fig. 4. Effect of T and DHT on cell proliferation in normal primary HOSE, immortalized HOSE, and malignant cells. Primarily HOSE (HOSE 693, HOSE 770, HOSE 783, and
HOSE 785), immortalized HOSE (HOSE 642, HOSE 301, HOSE 306, and HOSE 12-12), and OCa (OVCA 420, OVCA 429, OVCA 432, and OVCA 433) cell lines were cultured
as described in the legend of Fig. 2. After preincubation for 48 h, the cells were treated with different concentrations (1011 to 106 M) of T () and DHT () for 5 days. The cell
growth was assessed by MTT assay as described in “Materials and Methods.” The absorbance of wells not exposed to hormones was arbitrarily set as 1, and T- and DHT-treated cell
growth was expressed as the fold increase as compared with the control. The representative cell line from primary HOSE (HOSE 770), immortalized HOSE (HOSE 642), and malignant
(OVCA 420) cells is shown. The immortalized HOSE cell line (HOSE 306) and the malignant cell line (OVCA 433) that showed divergence from the other lines in their respective
groups are shown under the representative cell line. B, to confirm the specificity of T, 2  105 cells/T-25 flask were cultured alone (u) or cotreated with 108 M T (p) and two doses
of 4-hydroxy flutamide (105 M, f; 104 M, z) for 5 days. The control cells were treated with vehicle. After 5 days, the number of cells was counted. Treatment of cells with T and
DHT induced proliferation of cells in a dose-dependent manner in all of the cell lines. Cotreatment with 4-hydroxy flutamide abolished the response of normal HOSE cells to T. The
data shown are the mean of two experiments with triplicate samples and represent the mean  SD. , P  0.05.
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It has become clear with data from recent large case-control studies
that OCa risk is significantly increased in postmenopausal women
following long-duration ERT (18, 55–61). However, the mechanisms
underlying this association have not been established. Findings from
our present investigation have provided the first evidence that estro-
gens directly promote normal HOSE cell growth, which may favor
malignant transformation. Interestingly, normal HOSE cells were
found to be much more responsive to estrogen stimulation than their
immortalized or transformed counterparts. In addition, the major
postmenopausal estrogen, E1 (62), displayed equal potency as the
premenopausal ovarian-derived circulating estrogen, E2, in stimulat-
ing normal and malignant HOSE cell growth. Because E1 is a weak
ligand for estrogen receptors (63), the popular view maintains that this
estrogen exerts little estrogenic effect on target cells. Our data there-
fore provide a contrary perspective that suggests the effectiveness of
postmenopausal estrogen in promoting OSE cell proliferation. In
premenopausal women, circulating E2 ranges from 10–20 pg/ml dur-
ing the follicular and luteal phases and peaks at 200 pg/ml during
ovulation (52). These circulating E2 levels, at 3 1011 to 6 1010
M, are definitely effective in stimulating normal and malignant HOSE
cell growth under our culture conditions. In perimenopausal women,
E1 sulfate, which serves as a stable circulating reservoir of estrogen,
reaches levels as high as 100 pg/ml or 109 M. Ovaries of postmeno-
pausal women do not secrete estrogens, but postmenopausal women
have significant levels of E2 (9 pg/ml or 3  1011 M) and E1
(13.3–350 pg/ml or 4  1011 to 1  109 M) in their circulation
(64). These levels are still high enough to promote HOSE and OCa
cell growth, based on the results of the current study.
Appreciable evidence implicates androgen in the pathogenesis of
OCa. In premenopausal women, the circulating T levels are around
380 pg/ml or 109 M (52). Postmenopausal ovary is rich in androgen,
as evidenced by T concentrations seen in ovarian veins. T (21) and
DHT (37), at concentrations between 1011 and 106 M, are well
within the range capable of stimulating HOSE and OCa cell growth.
According to the inclusion cysts theory, normal HOSE cells entrapped
into inclusion cysts are predisposed to undergo neoplastic transfor-
mation, probably due to exposure to an androgen-rich stromal envi-
ronment (2, 9, 10). In the present study, we observed an AR- and
dose-dependent enhancement of cell growth in all normal and malig-
nant HOSE cell cultures/lines. The cellular androgen, DHT, is appar-
ently more potent than the circulating androgen, T, in simulating
normal HOSE cell growth. However, both androgens are equally
effective in stimulating OCa cell growth. The differential cellular
responses to T and DHT may be related to differential activities of
5-reductase in these cell lines (65). Our finding that OVCA 433 fails
to respond to both androgens could be explained by our previous
report of a complete loss of AR mRNA expression in this OCa cell
line (66). In addition, we have observed loss of AR expression in
several other OCa cell lines (66). Hence, although androgens may
play a significant role in the early genesis of OCa, such as when the
OSE is entrapped in inclusion cysts, their contribution in OCa growth
regulation may be significantly reduced during tumor progression in
postmenopausal women with declining androgen levels (67) and in
ovarian tumors with notable loss of AR expression (63).
Perhaps the most intriguing and novel finding of this study is the
inverted U-shape dose-response curves observed for many, but not all,
normal HOSE cell cultures in response to P4. P4 present at low doses
(1011 to 109 M) was proproliferative, whereas P4 present at higher
Fig. 5. Effect of P4 on cell growth in primary HOSE, immortalized normal HOSE, and malignant cell lines. Primarily HOSE (HOSE 693, HOSE 770, HOSE 783, and HOSE 785),
immortalized HOSE (HOSE 642, HOSE 301, HOSE 306, and HOSE 12-12), and OCa (OVCA 420, OVCA 429, OVCA 432, and OVCA 433) cell lines were cultured as described
in the legend of Fig. 2. A, the cells were treated with different concentrations (1011 to 106 M) of P4 (Œ) for 5 days. The cell growth was assessed by MTT assay as described in
“Materials and Methods.” The absorbance of wells not exposed to hormones was arbitrarily set as 1, and P4-treated cell growth was expressed as the fold increase/decrease as compared
with the control. The representative cell line from primary HOSE (HOSE 770), immortalized HOSE (HOSE 642), and malignant (OVCA 420) cells is shown. The primary cell line
(HOSE 693), immortalized HOSE cell line (HOSE 306), and malignant cell line (OVCA 433) that showed divergence from the other cell lines in their respective groups are shown
under the representative line. B, to confirm the specificity of P4, 2  105 cells/T-25 flask were cultured alone (u) or cotreated with 108 M P4 (p) and two doses of RU 38486 (105
M, f; 104 M, z) for 5 days. The control cells were treated with vehicle. After 5 days, the number of cells was counted. Treatment of cells with P4 inhibited proliferation of cells in
a dose-dependent manner in all cell lines tested. Cotreatment with RU 38486 abolished the response of normal HOSE cells to P4. The data are shown as the mean of two experiments
with triplicate samples and represent the mean  SD. , P  0.05.
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doses (108 to 106 M) was antiproliferative to most normal and
malignant HOSE cells. In premenopausal women, serum P4 levels
fluctuate in the range of 2–14 ng/ml or 6–47  109 M (52). The
higher concentrations are only reached during the midluteal phase of
the female cycle. Furthermore, a 10-fold increase in P4 is noted during
pregnancy (68). Previous studies on the influence of P4 on OCa cell
growth demonstrated a growth-inhibitory effect for the steroid (20,
36). Induction of apoptosis and p53 up-regulation were proposed as
mechanisms mediating the P4-induced growth-inhibitory action on
OCa cells (20). We recently obtained flow cytometry data to indicate
that all HOSE and OVCA cell lines die via apoptosis after treatment
with high doses of P4 (106 M).4 It is worthwhile to note that the
proproliferation effects of low-dose P4 on normal and malignant
HOSE cell cultures/lines have not been reported previously. Taken
together, the antiproliferative effects of P4 could explain the observed
protective effect offered by pregnancy, sometimes referred to as the
“pregnancy clearance effect” (19). According to this theory, preg-
nancy rids the OSE of early transformed cells. In this regard, our data
would suggest that only high levels of P4, which are present during
pregnancy, are effective in inducing massive cell death in the OSE and
therefore offer a cancer prevention effect. Ironically, lower levels of
P4, which are found during the luteal phase of the female cycle, are
likely to be proproliferative to the OSE. Thus, whereas pregnancy
may offer protection against ovarian carcinogenesis, continuous ovar-
ian cycling may increase OCa risk.
In conclusion, we have observed coexpression of FSH-R and LH-R
transcripts in all normal and malignant HOSE cell cultures/lines
examined. Our data have identified FSH, LH, E1, E2, T, DHT, and
low-dose P4 as positive growth regulators for HOSE cells. Con-
versely, P4 at high concentrations has been shown to be a potent
antiproliferative factor for HOSE cells. Collectively, these results
support the notion that elevated gonadotropin levels after menopause,
rising estrogen and P4 levels during the female cycle, exposure of
OSE to a high androgenic environment such as that seen in the
inclusion cysts, and exposure to exogenous estrogens such as that seen
during ERT are probable risk factors for OCa. Conversely, high levels
of P4 may offer protection against OCa development by ridding the
OSE of early transformed cells, hence providing a mechanistic expla-
nation for the phenomenon of pregnancy clearance effect. The puta-
tive protective effect of P4 also raises the issue of whether combined
estrogen and progestin replacement therapy is a safer alternative than
ERT with respect to OCa development.
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